GI Hepatobiliary

Hepatocellular Carcinoma

Localized

No Prior Therapy

Prior Therapy

1st Line

No Trials Currently Available

IRB # 19185
Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination with Pembrolizumab (MK-3475) Versus Lenvatinib in First-line Therapy of Participants with Advanced Hepatocellular Carcinoma

IRB # 20506
New study to be available soon

2nd line

IRB # 17603
Phase 1-2 Study of ADI-PEG 20 plus FOLFOX in Subjects with Advanced Gastrointestinal Malignancies Focusing on Hepatocellular Carcinoma

IRB # 20506
New study to be available soon

1st or 2nd Line

Cholangiocarcinoma

IRB # 20357
[NCI CIRB] A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers

IRB # 16033
New study to be available soon

IRB # 19095
A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302)

No Trials Currently Available

IRB # 2377
A humanitarian device exemption use protocol of TheraSphere for treatment of unresectable Hepatocellular Carcinoma

IRB # 20410
New study to be available soon

IRB # 17603
Phase 1-2 Study of ADI-PEG 20 plus FOLFOX in Subjects with Advanced Gastrointestinal Malignancies Focusing on Hepatocellular Carcinoma (LEAP-002)

CROSS-DISEASE TRIALS:

IRB# TBD
EAY131 (MATCH)

http://www.ohsu.edu/research/rda/so/knight.php

Key

- Open for Enrollment
- In Development
- Enrollment on Hold